Trial Profile
Portal hemodynamic effects of lenvatinib in patients with advanced hepatocellular carcinoma: a prospective cohort study
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 21 Oct 2020
Price :
$35
*
At a glance
- Drugs Lenvatinib (Primary)
- Indications Liver cancer
- Focus Pharmacodynamics
- 01 Sep 2020 Results (N=28), published in the Hepatology Research
- 21 Nov 2018 Status changed from not yet recruiting to recruiting.
- 22 Jun 2018 New trial record